Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Comparison of Rosuvastatin and Atorvastatin in Patients With Acute Coronary Syndrome

This study has been completed.
Information provided by (Responsible Party):
Dr. Stephen LaHaye, Queen's University Identifier:
First received: April 22, 2008
Last updated: March 28, 2016
Last verified: March 2016
This is a 3-month, randomized, parallel-group study with 2 periods, comparing the efficacy and the safety of rosuvastatin 20 mg versus atorvastatin 80 mg in patients with an acute coronary syndrome (ACS).

Condition Intervention Phase
Acute Coronary Syndromes
Drug: rosuvastatin
Drug: placebo
Drug: atorvastatin
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Comparison of the Effect Noted in The Apo/Apo-1 Ratio Using Rosuvastatin and Atorvastatin in Patients With acUte Coronary Syndrome CENTAURUS Study

Resource links provided by NLM:

Further study details as provided by Queen's University:

Primary Outcome Measures:
  • Compare efficacy of rosuvastatin 20 mg versus atorvastatin 80 mg in measuring ApoB/ApoA ratio at 3 months in acute coronary syndrome patients receiving the study treatment after percutaneous coronary intervention (PCI). [ Time Frame: 12 weeks ]

Secondary Outcome Measures:
  • Efficacy of rosuvastatin 20 mg versus atorvastatin 80 mg in reducing LDL-C 1 month and 3 months post PCI. [ Time Frame: 12 weeks ]
  • Efficacy of early-started rosuvastatin 20 mg versus placebo on hs-CRP from admission to start of study treatment post PCI. [ Time Frame: 12 weeks ]
  • Efficacy of rosuvastatin 20 mg versus atorvastatin 80 mg in reducing ApoB/ApoA-1 ratio at 1 month. [ Time Frame: 12 weeks ]

Enrollment: 18
Study Start Date: April 2006
Study Completion Date: September 2007
Primary Completion Date: September 2007 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: 1
Rosuvastatin 20 mg versus placebo 20 mg
Drug: rosuvastatin
rosuvastatin 20 mg from day 0 to (maximum) day 6
Drug: placebo
placebo 20 mg from day 0 to (maximum) day 6
Active Comparator: 2
rosuvastatin 20 mg versus atorvastatin 80 mg
Drug: rosuvastatin
rosuvastatin 20 mg from discharge until the end of the study
Drug: atorvastatin
atorvastatin 80 mg from discharge until the end of the study

  Show Detailed Description


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Men or women who are between 18 and 75 years old
  • Patients diagnosed with non ST elevation - acute coronary syndrome (NSTE-ACS)
  • Patients with onset of clinical symptoms less than 24 hours prior to their admission for which a PCI is planned or anticipated.

Exclusion Criteria:

  • Patients with STEMI (ST elevation myocardial infarction-heart attack) and primary PCI planned within 24 hours of admission will not be included.
  • Patients will not be allowed to have taken any cholesterol-lowering medications during 1 month prior to enrolment.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00665834

Canada, Ontario
Kingston General Hospital
Kingston, Ontario, Canada, K7L 2V7
Vascular Disease Prevention and Research Centre, Hotel Dieu Hospital
Kingston, Ontario, Canada, K7L 5G2
Sponsors and Collaborators
Queen's University
Principal Investigator: Stephen A LaHaye, MD Queen's University
  More Information

Responsible Party: Dr. Stephen LaHaye, Principal Investigator, Queen's University Identifier: NCT00665834     History of Changes
Other Study ID Numbers: DMED 938-06
Study First Received: April 22, 2008
Last Updated: March 28, 2016

Additional relevant MeSH terms:
Acute Coronary Syndrome
Pathologic Processes
Myocardial Ischemia
Heart Diseases
Cardiovascular Diseases
Vascular Diseases
Lipid Metabolism Disorders
Metabolic Diseases
Atorvastatin Calcium
Rosuvastatin Calcium
Anticholesteremic Agents
Hypolipidemic Agents
Molecular Mechanisms of Pharmacological Action
Lipid Regulating Agents
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Enzyme Inhibitors processed this record on April 27, 2017